Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 20/20 | 0.81 |
| ▸ | KLK1 | P06870 | 6/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14485596 | 1.00 | KLKB1 (0.81) | KLKB1KLK1 | |
| SCHEMBL15901620 | 1.00 | KLKB1 (0.81) | KLKB1KLK1 | |
| SCHEMBL14486163 | 0.90 | KLKB1 (0.85) | KLKB1KLK1 | |
| SCHEMBL14486085 | 0.90 | KLKB1 (1.00) | KLKB1KLK1 | |
| SCHEMBL14486086 | 0.90 | KLKB1 (1.00) | KLKB1KLK1 | |
| SCHEMBL14486159 | 0.90 | KLKB1 (0.85) | KLKB1KLK1 | |
| SCHEMBL15901509 | 0.90 | KLKB1 (0.75) | KLKB1KLK1 | |
| SCHEMBL22344727 | 0.90 | KLKB1 (0.75) | KLKB1KLK1 | |
| SCHEMBL14486095 | 0.89 | KLKB1 (0.83) | KLKB1KLK1 | |
| SCHEMBL14486088 | 0.89 | KLKB1 (0.83) | KLKB1KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200261383-A1 | PHARMACEUTICAL COMPOSITIONS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2020-08-20 | — | — | US | claimed |
| EP-2729443-B3 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2020-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261383-A1 | PHARMACEUTICAL COMPOSITIONS | ADCY9, PDE6D, PDE6G | KLKB1 4010/4885KLK1 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.